HER-2 Positive Breast Cancer Market in the US 2015-2019 is the latest addition to Sandlerresearch.org industry research reports collection. The report is about 108 pages published in March-2015. HER-2 Positive Breast Cancer Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.
Analysts forecast the HER-2 Positive Breast Cancer market in US to grow at a CAGR of 12.65 percent over the period 2014-2019. Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.
Covered in this Report This report covers the present scenario and the growth prospects of the HER-2 Positive Breast Cancer market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutics and chemotherapeutics used in the management of HER-2 positive breast cancer patients. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the HER-2 Positive Breast Cancer market in the US. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. The report HER-2 Positive Breast Cancer Market in US 2015-2019, has been prepared based on an indepth market analysis with inputs from industry experts. The report covers the market landscape of the HER-2 Positive Breast Cancer market in the US and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Buy Report @ http://www.sandlerresearch.org/purchase?rname=34236 .
Key Vendors Celgene F. Hoffmann-La Roche GlaxoSmithKline Novartis Sanofi
Other Prominent Vendors Bristol-Myers Squibb DARA BioSciences Eisai Hospira Pfizer ProStrakan Sun Pharmaceutical Industries Teva Pharmaceutical Inquire for Discount @ http://www.sandlerresearch.org/discount?rname=34236 .
Market Driver Increase in Population of Breast Cancer Patients
Market Challenge
Poor Diagnosis and Screening
Market Trend Increase in Awareness
Key Questions Answered in this Report What will the market size be in 2019 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors? Inquire Before buying the Report @ http://www.sandlerresearch.org/inquire-beforebuying?rname=34236 .
List of Exhibits: Exhibit 1: Market Research Methodology Exhibit 2: Pathophysiology: HER-2 Positive Breast Cancer Exhibit 3: Prevalence Data of HER-2 Positive Breast Cancer in the US, 2014 Exhibit 4: Prevalence Data of HER-2 Positive Breast Cancer in the US, 2014 (in percentage) Exhibit 5: Diagnosis of HER-2 Positive Breast Cancer: IHC Exhibit 6: Diagnosis of HER-2 Positive Breast Cancer: FISH Exhibit 7: Management of HER-2 Positive Breast Cancer
Exhibit 8: ASCO Treatment Guidelines: HER-2 Positive Breast Cancer Exhibit 9: Snapshot of Economic Burden of the HER-2 Positive Breast Cancer Market in US Exhibit 10: Snapshot of HER-2 Positive Breast Cancer Market in US 2014 Exhibit 11: HER-2 Positive Breast Cancer Market in US 2014-2019 (US$ million) Exhibit 12: Drivers and Challenges of the HER-2 Positive Breast Cancer Market in US Exhibit 13: HER-2 Positive Breast Cancer Market in US Segmentation by Type of Therapy Exhibit 14: HER-2 Positive Breast Cancer Market in the US Segmentation by Type of Therapy 2014 Exhibit 15: HER-2 Positive Breast Cancer Market in US Segmentation by Molecule Type Exhibit 16: HER-2 Positive Breast Cancer Market in US Segmentation by Molecule Type 2014 Exhibit 17: HER-2 Positive Breast Cancer Market in US Market Segmentation by Route of Administration Exhibit 18: HER-2 Positive Breast Cancer Market in US Segmentation by Route of Administration 2014 Exhibit 19: Buying Criteria Of HER-2 Positive Breast Cancer Market in US Exhibit 20: Drivers and their Impact on the Key Customer Category of the HER-2 Positive Breast Cancer Market in US Exhibit 21: 5-Year Survival Rate by Stage of Diagnosis (SEER analysis for 2004-2010) Exhibit 22: Revenue Comparison of Top Drugs for HER-2 Positive Breast Cancer in 2013 (US$ million) Exhibit 23: Product Portfolio: Celgene Exhibit 24: YoY Growth Rate and Global Revenue of Abraxane 2010-2013 (US$ million) Exhibit 25: Product Portfolio: F. Hoffmann-La Roche Exhibit 26: YoY Growth Rate and Revenue of Herceptin 2010-2013 (US$ million) Exhibit 27: Revenue of Perjeta for 2012-2013 (US$ million) Exhibit 28: YoY Growth Rate and Revenue of Xeloda 2010-2013 (US$ million) Exhibit 29: Product Portfolio: GlaxoSmithKline Exhibit 30: YoY Growth Rate and Revenue of Tykerb 2010-2013 (US$ million)
Exhibit 31: Product Portfolio: Novartis Exhibit 32: YoY Growth Rate and Revenue of Femara 2010-2013 (US$ million) Exhibit 33: Product Portfolio: Sanofi Exhibit 34: YoY Growth Rate and Global Revenue of Taxotere 2010-2013 (US$ million) Exhibit 35: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million) Exhibit 36: Celgene: Sales by Geography 2013 Exhibit 37: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013 Exhibit 38: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013 Exhibit 39: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division) Exhibit 40: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division) Exhibit 41: GlaxoSmithKline: Business Segmentation 2013 Exhibit 42: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion) Exhibit 43: GlaxoSmithKline: Sales by Geography 2013 Exhibit 44: GlaxoSmithKline: Pipeline Products 2013 Exhibit 45: Novartis AG: Business Segmentation Exhibit 46: Novartis AG: Revenue by Business Segmentation 2013 Exhibit 47: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million) Exhibit 48: Novartis AG: Revenue by Geographical Segmentation 2013 Exhibit 49: Sanofi SA: Business Segmentation Exhibit 50: Sanofi SA: Revenue by Business Segmentation 2013 Exhibit 51: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million) Exhibit 52: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Complete Report is Available @ http://www.sandlerresearch.org/her-2-positive-breast-cancermarket-in-the-us-2015-2019.html .
Browse All Reports on Pharmaceutical, Therapeutics HER-2 Positive Breast Cancer Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. Contact sales@sandlerresearch.org / Call +1 888 391 5441 for further information on “HER-2 Positive Breast Cancer Market in the US 2015-2019� report OR for any other market research and intelligence needs you may have for your business.